Innovative gene and cell therapies have the potential to treat previously incurable serious diseases. SaxoCell® is bringing strong German players from this field together to develop and produce these ‘living drugs’ for safe, effective and affordable treatment.

SaxoCell channels regional innovations towards the design, manu-facture and application of specialized therapeutic cells. Its vision: To establish a unique cell and gene therapy value chain and industry in Saxony by bundling comprehensive cell and gene therapy research expertise with industrial R&D expertise – and bringing it together with novel technologies including artificial intelligence, automation, Omics technologies and others.

As a cluster of leading research institutes and medical facilities which extends across the Free State of Saxony in Eastern Germany, SaxoCell has found a strong partner in Leipzig and its institutions:

• The City of Leipzig has provided support from SaxoCell’s inception and is committed to the consortium’s success
• The Fraunhofer Institute for Cell Therapy and Immunology IZI plays a valuable role within SaxoCell due to its expertise in the field of cell and gene therapy R&D and its specialized infrastructure (e.g. clean-room facilities)
• University Hospital Leipzig is a SaxoCell partner, and the city’s university offers excellent basic, applied and clinical research in areas relevant to SaxoCell’s goals

Last but not least, critical infrastructure such as the Halle-Leipzig airport with its high-performance logistics providers make the city an attractive member of the SaxoCell consortium.

SaxoCell enables the novel cell and gene therapies or ATMPs (Advanced Therapy Medicinal Products) which its partners develop to quickly reach patients with previously hard-to-treat serious diseases – thus providing them with new hope for the future.